Search Results

Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. Deciphering the role of GPCRs in obesity pathology for drug development GPCR Events, Meetings, and Webinars 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual

GPCR Binders, Drugs, and more Modelling altered signalling of G-protein coupled receptors in inflamed environment to advance drug design. GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit | February 21-23, Boston. Biological Sciences Doctoral Training Programme Senior QM Manager Director of Molecular Pharmacology, Discovery Discovery Explore Dr.

Kenakin’s Emerging Drug Hunter  lecture delivers exclusive, cutting-edge insights that help you move This is about accelerating your path from discovery to clinic, without wasted cycles or missteps.     the Myth of High and Low Affinity Binding Sites Could Be Slowing Your Pipeline   If you’re working in drug discovery, you know the pressure: timelines are tight, resources finite, and decisions must be fast

September 2022 "GPCRs are the most potential targets for drug discovery, however, their role in oncology is underappreciated and GPCR-based anti-cancer drug is not fully investigated.

Predicting based on Dynamic Deep Transfer Learning Reviews, GPCRs, and more Key Aspects of Modern GPCR Drug Discovery Location bias: A "Hidden Variable" in GPCR pharmacology Structural and Molecular Insights Discovery Engine and Pipeline of Small Molecule Therapeutics Reproducibility of Tanso Biosciences' GPCR Final Symposium September 7 - 8, 2023 | 3rd Transatlantic ECI GPCR Symposium September 25 - 28, 2023 | Discovery On Target September 27 - 28, 2023 | Training Seminar "The Renaissance in GPCRs as Drug Targets: Allosteric

venture-backed clinical stage international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, today announced four appointments

Discovery? Robert Lefkowitz, Howard Rockman for their review G Protein-Coupled Receptors: A Century of Research and Discovery , and more Target-based discovery of antagonists of the tick (Rhipicephalus microplus) kinin receptor receptor-like proteins in rice (Oryza sativa) G Protein-Coupled Receptors: A Century of Research and Discovery discovery October 2024 | Biologics US 2024 October 2 - 4, 2024 | 9th GPCRs in Medicinal Chemistry October

Targeting in silico GPCR conformations with ultra-large library screening for hit discovery. Christopher Prior, as CEO and Reports Recent Drug Discovery Highlights Call for GPCR Papers GPCRs: Signal GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit, (February 21 - 23, 2023) Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug

into some novel strategies, including allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic response."

into some novel strategies, including allosterism and the targeting of oligomers, which may increase drug discovery success and enhance the therapeutic response."

SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its half-year and second quarter financial results for the

Location-biased activation of the proton-sensor GPR65 is uncoupled from receptor trafficking GPCR Binders, Drugs glass microfiber membranes as a label-free strategy for hit identification Reviews, GPCRs, and more The discovery Carolina semaglutide plant Excellerate Bioscience Announces Site Relocation AI can help to speed up drug discovery — but only if we give it the right data Inversago Pharma divulges new cannabinoid CB1 receptor antagonists BenevolentAI, Exscientia on the comeback trail after securing separate AI drug discovery

GPCR Binders, Drugs, and more Discovery of SYD5115, a novel orally active small molecule TSH-R antagonist In situ visualization of opioid and cannabinoid drug effects using phosphosite-specific GPCR antibodies Industry News A Current View of Allosteric GPCR Drug Discovery from the 2nd Annual GPCRs-Targeted Drug Discovery Summit, Boston MA Pathios Therapeutics Unveils PTT-4256, a Highly Potent and Selective Inhibitor Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

GPCR Binders, Drugs, and more A snake toxin as a theranostic agent for the type 2 vasopressin receptor (March 30, 2023) NEW Webinar - Antiverse: Engineering the Future of Drug Discovery (March 30, 2023) NEW Molecular Dynamics in Pharma (March 31, 2023) NEW FREE Workshop - Challenges in GPCR Drug Discovery Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

P2X4 receptor] Osmotic stress studies of G-protein-coupled receptor rhodopsin activation GPCR Binders, Drugs , and more Chimeric antigens displaying GPR65 extracellular loops on a soluble scaffold enabled the discovery Exhibition February 11 - 14, 2024 | 2024 BPS Annual Meeting March 5 - 7, 2024 | 3rd GPCRs - Targeted Drug Discovery Summit March 23 - 24, 2024 | Ligand Recognition and Molecular Gating Seminar March 24 - 29 , 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery

ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that patient enrollment has been completed in its Phase 2a

GPCRs Re-Enter the Story — Not as Theory, but as Tools GPCRs have always been powerful drug targets — yet challenging to drug. The “Aha” Moment — Ten Years in the Making Many discoveries unfold slowly — dozens of experiments that extended beyond classical ligand models.Collaboration and long-term persistence proved essential to discovery Emerging direction: Peptide–drug conjugates for precision targeting.

ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has moved a selective and potent M4 muscarinic receptor

transmembrane sites for accurate characterization, binding-affinity calculations, and lead optimization in drug discovery."

Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery Chemistry April 4 - 7, 2024 | American Physiology Summit April 5 - 10, 2024 | AACR Annual

Develop AI-driven Pipeline of Precision-Engineered Medicines "Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia’s AI-based capabilities and personalised

Nicole Perry-Hauser, on her selection as a 2024 Discovery Science Emerging Scholar at Vanderbilt University of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism GPCR Binders, Drugs Exhibition February 11 - 14, 2024 | 2024 BPS Annual Meeting March 5 - 7, 2024 | 3rd GPCRs - Targeted Drug Discovery Summit March 23 - 24, 2024 | Ligand Recognition and Molecular Gating Seminar March 24 - 29 , 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery

mobilization, and ERK phosphorylation have been pivotal in deciphering GPCR activity, particularly in drug discovery endeavors [2]. ability to provide real-time readouts of pharmacological activity, allowing for the determination of drug kinetics—a critical aspect in drug development [14]. discovery efforts by enabling the precise characterization of pharmacological interventions in real

Scylla paramamosain Reshaping the yeast galactose regulon via GPCR signaling cascade GPCR Binders, Drugs Research Direct Binding Methods to Measure Receptor-Ligand Interactions How accurately can one predict drug Exhibition February 11 - 14, 2024 | 2024 BPS Annual Meeting March 5 - 7, 2024 | 3rd GPCRs - Targeted Drug Discovery Summit March 23 - 24, 2024 | Ligand Recognition and Molecular Gating Seminar March 24 - 29 , 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug Discovery

Brian Shoichet, Bryan Roth, et al. for their research on AlphaFold2 structures guide prospective ligand discovery Prototypic G Protein-Coupled Adenosine A2A Receptor AlphaFold2 structures guide prospective ligand discovery 1/GIP receptor agonist CT-388 in people with obesity Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024 𝐈𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐢𝐧𝐠 𝐀𝐋𝐋𝐎𝐃𝐃: 𝐀𝐥𝐥𝐨𝐬𝐭𝐞𝐫𝐲 𝐢𝐧 𝐃𝐫𝐮𝐠 Discovery’ June 9 - 14, 2024 | 2024 Phosphorylation and G-Protein Mediated Signaling Networks June 25

Conventional GPCR drug discovery has largely focused on orthosteric sites, but recent breakthroughs in understanding allosteric modulation have opened up new avenues for drug development. discovery. Over the past decade, there has been a notable growth in the discovery of allosteric modulators for GPCRs Allosteric modulation is gaining prominence in GPCR therapeutics, with the discovery of an intracellular

Engineering G protein-coupled receptors for stabilization Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism Chemogenetic Signaling in Space and Time: Considerations for June 4, 2024 | Live Webinar ‘It All Starts With a Protein – Protein Sciences as a Key to Success in Drug Discovery’ June 9 - 14, 2024 | 2024 Phosphorylation and G-Protein Mediated Signaling Networks June 25

ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it has entered into a definitive agreement with Armistice

Her work in the field has been instrumental and is set to shape the future of drug discovery for years